Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

7,150 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    USDA Deregulates American Chestnut Genetically Engineered For Enhanced Blight Tolerance

    The USDA's Animal and Plant Health Inspection Service has determined that genetically engineered American Chestnut trees, developed for enhanced tolerance to chestnut blight fungus, no longer require regulatory oversight. This landmark decision follows extensive evaluation of scientific data, public comments, and plant pest risk assessments submitted by the State University of New York College of Environmental Science and Forestry.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Bergeson & Campbell
    Bergeson & Campbell
  • Article

    USDA Issues Final Rule On Federal Procurement Guidelines For Biobased Products

    USDA issued a final rule amending regulations concerning Guidelines for Designating Biobased Products for Federal Procurement.
    United StatesFood, Drugs, Healthcare, Life Sciences
Jones Day
Jones Day
  • Article

    USDA Proposes Rule Adding Terms For Biologics To Animal Test Results

    USDA's Animal and Plant Health Inspection Service proposed amending the veterinary biological product regulations.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    Wall Street Journal Features Nanopore, High Speed, Cheap Gene Sequencing As 2012 Closes

    The Wall Street Journal this week featured nanopore sequencing in its year end review of important health trends (both hard copy and electronic copies).
    United StatesFood, Drugs, Healthcare, Life Sciences
    Foley & Lardner LLP
    Foley & Lardner LLP
  • Article

    White House Orders Inventory Of Infectious Agents At Federally Funded Labs

    The memo ordered all federally funded labs that handle animal or plant materials that are infectious agents or toxins to spend a month reviewing safety and security plans.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    Prosecution Pointer 110

    The USPTO Checker Version 4.4.6 is a Microsoft Windows-based software application for checking biotechnology Sequence Listings for compliance with format and content rules.
    United StatesIntellectual Property
    Finnegan, Henderson, Farabow, Garrett & Dunner LLP
    Finnegan, Henderson, Farabow, Garrett & Dunner LLP
  • Article

    Why Broad Functional Patent Claims Suppress Medical Innovation

    Head of Life Sciences Irena Royzman authored a Bloomberg Law article titled "Why Broad Functional Patent Claims Suppress Medical Innovation" on Jan. 9, 2023.
    United StatesIntellectual Property
    Herbert Smith Freehills Kramer LLP
    Herbert Smith Freehills Kramer LLP
  • Article

    EMA Completes Zydelig Review

    The PRAC's recommendations will now be passed to EMA's Committee for Medicinal Products for Human Use, or CHMP, for adoption of the Agency's final position.
    European UnionFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    EMA Consultation On The Revised Policy On Access To Documents

    The EMA has launched a public consultation on the proposed revision to its policy on access to documents.
    European UnionFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    EMA Consults On Viral Safety Of Plasma-Derived Medicinal Products And Hepatitis E

    On June 25, 2015, EMA published a draft reflection paper on viral safety of plasma-derived medicinal products with respect to hepatitis E virus.
    European UnionFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    EMA Recommends Approval Of New Gene Therapy For Ultra-Rare Immune Disorder

    The CHMP opinion will now be sent to the European Commission for the adoption of a decision on an EU-wide MA.
    European UnionFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    EMA Recommends New Safety Measures For Zydelig

    Along with other recommendations, PRAC recommends that all patients treated with Zydelig receive antibiotics to prevent a particular type of lung infection...
    European UnionFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    EMA Tweaks Guidelines For Clinical Trial Data Transparency

    On June 12, the European Medicine Agency accepted, in principle, new transparency guidelines regarding the proactive disclosure of clinical trial data.
    European UnionFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    EMA Updates Organizational Structure

    It is not anticipated that interactions between stakeholders and the Agency will be affected by these changes.
    European UnionFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    Episode 281: Can The European Union Order Twitter To Silence President Trump?

    In our 281st episode of The Cyberlaw Podcast, Stewart Baker is joined by David Kris (@DavidKris) and Nick Weaver (@ncweaver) to discuss
    European UnionFood, Drugs, Healthcare, Life Sciences
    Steptoe LLP
    Steptoe LLP
  • Article

    New EMA Guidelines On Good Pharmacovigilance Practices

    The GVP guidance was effective on August 16, 2016.
    European UnionFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    Proposals To Revise Guidance On First-In-Human Clinical Trials

    EMA is proposing changes to current guidance on first-in-human clinical trials with the aim of improving strategies to identify and mitigate risks to trial participants.
    European UnionFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    Alkem Subsidiary Enzene Launches Adalimumab Biosimilar In India

    As reported by HealthCareRadius in India, on February 23, 2023, Enzene Biosciences, a subsidiary of Alkem Laboratories, announced commencement of commercial supplies of its biosimilar adalimumab (ENZ-129)...
    GlobalFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    China NMPA Approves TYVYT (sintilimab) In Combination With Chemotherapy For Gastric Cancer

    On June 24, 2022, Innovent Biologics, Inc. and Eli Lilly and Company announced that the National Medical Products Administration (NMPA) of China approved the supplemental New Drug Application (sNDA) for...
    GlobalFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    China’s Biotech Rise, Healthcare Today

    Partners Emmanuelle Trombe and Anthony Paronneau examine China's emergence as a global biotechnology innovation hub, exploring cross-border collaboration models and critical considerations for life sciences companies engaging in China-related transactions. The analysis covers intellectual property protection, regulatory compliance frameworks, data management protocols, and foreign investment screening requirements.
    GlobalFood, Drugs, Healthcare, Life Sciences
    McDermott Will & Schulte
    McDermott Will & Schulte
  • Showing 41–60 of 7150 results

    PreviousNext
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics